Getinge Group Q4 report 2012

  Getinge Group Q4 report 2012

Business Wire

GETINGE, Sweden -- January 25, 2013

Regulatory News:

Getinge AB (STO:GETIB):

Reporting period January – December

  *Order intake rose by 10.9% to SEK 24,416 M (22,012), and grew organically
    by 2.7% · Net sales increased by 11.0% to SEK 24,248 M (21,854), and grew
    organically by 2.8%
  *Profit before tax declined by 0.2% to SEK 3,436 M (3,444)
  *Net profit decreased by 0.2% to SEK 2,531 M (2,537)
  *Earnings per share declined by 0.3% to SEK 10.58 (10.61)
  *EBITA before restructuring rose by 6.1% to SEK 4,849 M (4,571)
  *A dividend per share of SEK 4.15 (3.75) is proposed, corresponding to
    SEK989 M (894)
  *Favourable profit outlook for 2013

Reporting period October – December

  *Order intake rose by 3.3% to SEK 6,648 M (6,433), and declined organically
    by 1.3%.
  *EBITA before restructuring rose by 1.1% to SEK 1,943 M (1,921).
  *Acquisition of TSS completed

Order intake

The Group’s order intake experienced a weaker trend than expected during the
fourth quarter of the year, declining organically by 1.3%. For the full-year,
order intake increased organically by nearly 3%. The weak order performance
during the final quarter of the year was primarily due to Western European
markets. Historically, public-sector customers, primarily in Western Europe,
have used surplus funds to place supplementary orders during the final quarter
of the financial year. These orders with short lead times declined somewhat
during the most recent quarter. In North America, the volume trend was
favourable, and in the markets outside North America and Western Europe, the
trend was somewhat weaker compared with a stronger fourth quarter of 2011.
From a full-year and fourth-quarter perspective, demand and order intake for
consumables, disposables and services experienced a highly favourable trend
compared with 2011. Demand for medical-technical capital goods has diminished,
mainly in the heavily indebted Western European economies.

From a business-area perspective, the overall trend for the quarter was weak
due to the aforementioned reasons. For Medical Systems, order intake grew
organically by 1.0% during the quarter, while order intake for the 12-month
period increased organically by a very healthy 6.1%. Extended Care’s order
intake declined by 5.3% during the quarter, due to a weak trend in Western
Europe and North America. For Infection Control, where order intake decreased
organically by 2.5% during the quarter, demand from Life Science customers was
the main source of weakness.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander 25 January 2013
at 2:00 p.m. Swedish time

Swedish dial in number: +46 8 5352 6408

UK dial in number: +44 20 3364 5381

US dial in number: +1 646 254 3366

Participant passcode: 7506740

GETINGE GROUP is a leading global provider of products and systems that
contribute to quality enhancement and cost efficiency within healthcare and
life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and
MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

This information was brought to you by Cision


Getinge Group
Kornelia Rasmussen
Group Communications Director
+46 10 335 58 10
+46 10 335 58 10
Press spacebar to pause and continue. Press esc to stop.